CYP2C19 and Hypoalbuminemia: Previous studies have identified factors influencing voriconazole-related hepatotoxicity, including hypoalbuminemia, voriconazole plasma concentrations, and CYP2C19 genetic polymorphisms (Xiao et al., 2023).